64037-15-6

Usage

Uses

Used in Organic Synthesis:
5-Methylbenzoxazole-2-amine is used as a key intermediate in the synthesis of various organic compounds. Its unique structure and reactivity make it a valuable building block for the development of new molecules with potential applications in different industries.
Used in Pharmaceutical Manufacturing:
5-Methylbenzoxazole-2-amine is used as a starting material or a component in the production of various pharmaceuticals. Its presence in the final product can contribute to the drug's efficacy, stability, or other desired properties.
Used in Medicinal Chemistry Research:
5-Methylbenzoxazole-2-amine is used as a research compound in medicinal chemistry. Its biological activities and potential interactions with biological targets make it an interesting subject for the development of new therapeutic agents.
Used in Drug Design and Development:
5-Methylbenzoxazole-2-amine is used as a template or a scaffold in drug design and development. Its structural features can be modified to create new molecules with improved pharmacological properties, such as increased potency, selectivity, or reduced side effects.
Used in Chemical Research and Development:
5-Methylbenzoxazole-2-amine is used as a research compound in various chemical research and development projects. Its unique properties and reactivity can provide insights into new reaction mechanisms, catalysts, or other chemical processes.

InChI:InChI=1/C8H8N2O/c1-5-2-3-7-6(4-5)10-8(9)11-7/h2-4H,1H3,(H2,9,10)

Upstream product

• 10531-78-9 5-methyl-1,3-benzoxazole 
• 7664-41-7 ammonia 
• 95-84-1 3-amino-4-hydroxytoluene 
• 506-68-3 bromocyane 
• 90564-72-0 3-amino-6-methyl-benzo[1,4]oxazin-2-ylideneamine 

Downstream Products

• 129227-39-0 2-Chloro-N-(5-methyl-benzooxazol-2-yl)-benzamidine 
• 129227-07-2 2-Methyl-N-(5-methyl-benzooxazol-2-yl)-benzamidine 
• 22876-15-9 5-methylbenzo[d]oxazol-2(3H)-one 
• 38334-93-9 N-m-Methylbenzoyl-thioharnstoff 
• 128406-96-2 6-Methyl-4-m-tolyl-9-oxa-1,3,4a-triaza-fluorene-2-thione 
• 129227-38-9 4-Methoxy-N-(5-methyl-benzooxazol-2-yl)-benzamidine 
• 129227-18-5 2-(4-Methoxy-phenyl)-7-methyl-benzo[4,5]oxazolo[3,2-b][1,2,4]triazole 
• 129227-19-6 2-(2-Chloro-phenyl)-7-methyl-benzo[4,5]oxazolo[3,2-b][1,2,4]triazole 
• 129227-20-9 2-(4-Chloro-phenyl)-7-methyl-benzo[4,5]oxazolo[3,2-b][1,2,4]triazole 
• 129227-16-3 7-Methyl-2-o-tolyl-benzo[4,5]oxazolo[3,2-b][1,2,4]triazole 
• 129227-17-4 7-Methyl-2-p-tolyl-benzo[4,5]oxazolo[3,2-b][1,2,4]triazole 
• 129227-15-2 7-Methyl-2-phenyl-benzo[4,5]oxazolo[3,2-b][1,2,4]triazole 
• 38334-94-0 (4-chloro-benzoyl)-thiourea 
• 128406-97-3 4-(4-Chloro-phenyl)-6-methyl-9-oxa-1,3,4a-triaza-fluorene-2-thione 

Relevant academic research and scientific papers

Design, synthesis, and evaluation of substituted 2-acylamide-1,3-benzo[d]zole analogues as agents against MDR- and XDR-MTB

N-(5-Chlorobenzo[d]oxazol-2-yl)-4-methyl-1,2,3-thiadiazole-5-carboxamideox-amide has been identified as a potent inhibitor of Mtb H37Rv, with a minimum inhibitory concentration (MIC) of 0.42 μM. In this study, a series of substituted 2-acylamide-1,3-zole analogues were designed and synthesized, and their anti-Mtb activities were analyzed. In total, 17 compounds were found to be potent anti-Mtb agents, especially against the MDR- and XDR-MTB strains, with MIC values 10 μM. These analogues can inhibit both drug-sensitive and drug-resistant Mtb. Four representative compounds were selected for further profiling, and the results indicate that compound 18 is acceptably safe and has favorable pharmacokinetic (PK) properties. In addition, this compound displays potent activity against Gram-positive bacteria, with MIC values in the range of 1.48–11.86 μM. The data obtained herein suggest that promising anti-Mtb candidates may be developed via structural modification, and that further research is needed to explore other compounds.

Substituted benzo - 1, 3 - [...] compound, its preparation and use

The invention relates to a substituted benzo-1, 3-miscellaneous azole compound shown in the general formula I, and further relates to a preparation method of the compound and application to the preparation of antituberculosis drugs. The compound provided by the invention has effect not only on mycobacterium tuberculosis sensitive strains, but also on resistant strains which have drug resistance to isoniazid, rifampicin, and other traditional frontline antituberculosis drugs, and is a novel antimycobacterium tuberculosis compound.

A metal-free oxidative amination of benzoxazoles with primary amines and ammonia

An efficient synthesis of 2-aminobenzoxazoles is described by a direct oxidative amination of unfunctionalized benzoxazoles with primary amines. The reaction could be performed in the absence of transition metals by using catalytic amounts of a quaternary ammonium iodide and tert-butylhydroperoxide as a cheap and easy-to-handle co-oxidant. In addition to primary amines, aqueous solutions of NH3 were used to introduce a primary amine group into the heterocyclic core. Georg Thieme Verlag Stuttgart. New York.

Cobalt- and manganese-catalyzed direct amination of azoles under mild reaction conditions and the mechanistic details

A bonding moment: A new cobalt- or manganese-catalyzed amination of azoles has been developed using peroxide and an acid additive to couple various types of azoles with ammonia, and primary or secondary amines (see scheme). The catalyst loadings are low, the optimal reaction conditions are mild, and the substrate scope is broad. The product azoles are an important pharmacophore of high biological activity. Copyright

Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182

The present invention relates to processes and intermediates for the preparation of 6-11 bicyclic erythromycin derivative known as EDP-182 (IX-a). In particular, the present invention relates to processes and intermediates for the preparation of O-(2-amin

6-11 Bridged oxime erythromycin derivatives

The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes processes by which to make the compounds of the present invention.

6-11 Bridged oxime erythromycin derivatives

The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes processes by which to make the compounds of the present invention.